Gain Therapeutics, Inc. (NASDAQ:GANX) shares rose 3.4% in premarket trading on Monday after the biotechnology company reported first-quarter results that came in ahead of analyst expectations.
The clinical-stage biotech group posted an adjusted quarterly loss of $0.13 per share for the period ended March 31, 2026, slightly better than the consensus forecast of a $0.14 per share loss.
Net Loss Widens as Development Spending Increases
Gain Therapeutics reported a net loss of $5.6 million for the quarter, compared with a loss of $4.5 million during the same period last year.
Research and development expenses increased to $2.8 million from $2.3 million year-over-year, driven primarily by continued investment in the development of GT-02287 and unfavorable foreign exchange movements.
General and administrative costs also rose to $2.6 million, compared with $2.1 million in the prior-year quarter.
“The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 2025 related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson’s disease with or without a GBA1 mutation,” said President and CEO Gene Mack.
Company Highlights Progress in Parkinson’s Program
Gain Therapeutics said it presented additional Phase 1b clinical data for GT-02287 during the AD/PD 2026 conference held in March.
According to the company, the data demonstrated central target engagement and signs of clinical improvement among study participants.
As of March 2026, 14 of the 16 participants enrolled in the nine-month extension study had completed five months of treatment, with MDS-UPDRS scores remaining stable across a 150-day period.
Phase 2 Study Remains on Track for 2026
The company said it expects to receive FDA clearance for its Investigational New Drug (IND) application during the second quarter of 2026.
Gain Therapeutics added that it remains on schedule to launch its Phase 2 clinical trial during the third quarter of 2026.
Results from the ongoing Phase 1b study are expected to be released in the fourth quarter of 2026.